Details of the Drug Combination

General Information of Drug Combination (ID: DC1HU8S)

Drug Combination Name
Heparin Abciximab
Indication
Disease Entry Status REF
Angioplasty, Transluminal, Percutaneous Coronary Phase 1 [1]
Component Drugs Heparin   DM4ZP3W Abciximab   DMJO6GV
Small molecular drug Monoclonal antibody

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Heparin
Disease Entry ICD 11 Status REF
Aplastic anemia 3A70 Approved [2]
Bacteremia 1A73 Approved [2]
Burns N.A. Approved [2]
Coronary heart disease BA80.Z Approved [2]
Deep vein thrombosis BD71 Approved [2]
Disseminated intravascular coagulation 3B20 Approved [2]
Metabolic disorder 5C50-5D2Z Approved [2]
Pneumonia CA40 Approved [2]
Pulmonary embolism BB00 Approved [2]
Venous thrombosis BA43 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Diabetic angiopathy BD53.Y Investigative [2]
Indication(s) of Abciximab
Disease Entry ICD 11 Status REF
Acute disease N.A. Approved [5]
Angina pectoris BA40 Approved [6]
Brain ischaemia 8B1Z Approved [7]
Abciximab Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) TT38RM1 ITA2B_HUMAN; ITB3_HUMAN Modulator [8]
------------------------------------------------------------------------------------
Abciximab Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Integrin alpha-IIb (ITGA2B) OT4Y17PY ITA2B_HUMAN Increases ADR [9]
Integrin beta-3 (ITGB3) OTWCK1K6 ITB3_HUMAN Increases ADR [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00269880) A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
2 Heparin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 090809.
4 Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732.
5 Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004 Oct 26;110(17):2747-71.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6584).
7 Emergent carotid stenting and intra-arterial abciximab in acute ischemic stroke due to tandem occlusion. Br J Neurosurg. 2017 Oct;31(5):573-579.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.